title: Expression of excision repair cross-complementation group 1, breast cancer susceptibility 1, and β III-tubulin in thymic epithelial tumors.
abstract: BACKGROUND
  We investigated the clinical significance of excision repair cross-complementation group 1 (ERCC1), breast cancer susceptibility 1 (BRCA1), and class III β-tubulin (TUBB3) expression in thymic epithelial tumors.
  
  
  METHODS
  Fifty-six patients with thymic epithelial tumors were included in this study. Tumors sections were stained by immunohistochemistry for ERCC1, BRCA1, TUBB3, microvessel density, and p53.
  
  
  RESULTS
  ERCC1, BRCA1, and TUBB3 were expressed in 48%, 50%, and 27%, respectively. The expression of ERCC1, BRCA1, and TUBB3 was significantly correlated with the grade of malignancy in thymic epithelial tumors. These biomarkers were closely associated with p53 and microvessel density and were a prognostic marker for predicting poor outcome. We also found that overexpression of ERCC1 and TUBB3 was associated with resistance to platinum- and taxane-based chemotherapy.
  
  
  CONCLUSIONS
  An expression of ERCC1, BRCA1, and TUBB3 was correlated strongly with each other and was significantly associated with a poor outcome in thymic epithelial tumors. High-ERCC1 and TUBB3 expressions might be associated with resistance to platinum- and taxane-based chemotherapy, respectively.
authors.affiliation: Division of Thoracic Oncology, Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan. kkaira1970@yahoo.co.jp
authors.forename: Kyoichi
authors.initials: K
authors.lastname: Kaira
authors.forename: Masakuni
authors.initials: M
authors.lastname: Serizawa
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Koh
authors.forename: Satoru
authors.initials: S
authors.lastname: Miura
authors.forename: Rieko
authors.initials: R
authors.lastname: Kaira
authors.forename: Masato
authors.initials: M
authors.lastname: Abe
authors.forename: Kazuo
authors.initials: K
authors.lastname: Nakagawa
authors.forename: Yasuhisa
authors.initials: Y
authors.lastname: Ohde
authors.forename: Takehiro
authors.initials: T
authors.lastname: Okumura
authors.forename: Tateaki
authors.initials: T
authors.lastname: Naito
authors.forename: Haruyasu
authors.initials: H
authors.lastname: Murakami
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Takahashi
authors.forename: Haruhiko
authors.initials: H
authors.lastname: Kondo
authors.forename: Takashi
authors.initials: T
authors.lastname: Nakajima
authors.forename: Masahiro
authors.initials: M
authors.lastname: Endo
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Yamamoto
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019313:BRCA1 Protein / Q000378:metabolism*; D004268:DNA-Binding Proteins / Q000378:metabolism*; D004720:Endonucleases / Q000378:metabolism*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D015996:Survival Rate; D013953:Thymus Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D016896:Treatment Outcome; D014404:Tubulin / Q000378:metabolism*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
chemical_list: D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D004268:DNA-Binding Proteins; D009944:Organoplatinum Compounds; C495901:TP53 protein, human; C498585:TUBB3 protein, human; D014404:Tubulin; D016159:Tumor Suppressor Protein p53; C071447:ERCC1 protein, human; D004720:Endonucleases